DE69129302D1 - Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen - Google Patents

Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen

Info

Publication number
DE69129302D1
DE69129302D1 DE69129302T DE69129302T DE69129302D1 DE 69129302 D1 DE69129302 D1 DE 69129302D1 DE 69129302 T DE69129302 T DE 69129302T DE 69129302 T DE69129302 T DE 69129302T DE 69129302 D1 DE69129302 D1 DE 69129302D1
Authority
DE
Germany
Prior art keywords
tgf
beta
methods
fabrics
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69129302T
Other languages
English (en)
Other versions
DE69129302T2 (de
Inventor
Kenneth Iwata
J Foulkes
Dijke Peter Ten
John Haley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSI Pharmaceuticals LLC
Original Assignee
Oncogene Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogene Science Inc filed Critical Oncogene Science Inc
Application granted granted Critical
Publication of DE69129302D1 publication Critical patent/DE69129302D1/de
Publication of DE69129302T2 publication Critical patent/DE69129302T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
DE69129302T 1990-06-25 1991-06-25 Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen Expired - Lifetime DE69129302T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/543,341 US5262319A (en) 1985-04-19 1990-06-25 Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
PCT/US1991/004540 WO1992000330A1 (en) 1990-06-25 1991-06-25 Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof

Publications (2)

Publication Number Publication Date
DE69129302D1 true DE69129302D1 (de) 1998-05-28
DE69129302T2 DE69129302T2 (de) 1998-12-03

Family

ID=24167596

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69129302T Expired - Lifetime DE69129302T2 (de) 1990-06-25 1991-06-25 Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen

Country Status (10)

Country Link
US (1) US5262319A (de)
EP (1) EP0536275B1 (de)
JP (1) JPH05509312A (de)
AT (1) ATE165395T1 (de)
AU (1) AU657913B2 (de)
CA (1) CA2084510A1 (de)
DE (1) DE69129302T2 (de)
DK (1) DK0536275T3 (de)
ES (1) ES2120416T3 (de)
WO (1) WO1992000330A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6559123B1 (en) * 1985-04-19 2003-05-06 Osi Pharmaceuticals, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5824297A (en) * 1990-06-25 1998-10-20 Oncogene Science, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6204240B1 (en) 1991-11-22 2001-03-20 Genentech, Inc. TGF-β1 to improve neural outcome
US5460810A (en) * 1992-09-02 1995-10-24 Genetics Institute, Inc. Method for maintaining gut epithelial cells by treatment with a cytokine such as interleukin 11
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) * 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5445941A (en) * 1993-06-21 1995-08-29 Eli Lilly And Company Method for screening anti-osteoporosis agents
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
JP3398255B2 (ja) 1995-04-03 2003-04-21 賢二 坂本 新規ペプチド及びそれを有効成分とする骨疾患治療薬
US6071881A (en) * 1996-04-03 2000-06-06 Sakamoto; Kenji Peptides and remedy for bone diseases containing the same as active ingredient
DE69637316T2 (de) * 1995-06-07 2008-08-28 Poniard Pharmaceuticals, Inc., Seattle Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
US6306575B1 (en) * 1995-06-16 2001-10-23 Stemcell Technologies, Inc. Methods for preparing enriched human hematopoietic cell preparations
US6117985A (en) 1995-06-16 2000-09-12 Stemcell Technologies Inc. Antibody compositions for preparing enriched cell preparations
US7368111B2 (en) * 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
WO1998007032A1 (en) * 1996-08-16 1998-02-19 Metra Biosystems, Inc. Method and kit for assessing bone resorption
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
WO2000001410A1 (en) 1998-07-06 2000-01-13 Beth Israel Deaconess Medical Center Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US6773704B1 (en) * 1999-10-28 2004-08-10 The Brigham And Women's Hospital, Inc. Methods of treating vascular disease associated with cystatin C deficiency
US20040197333A1 (en) * 2000-02-10 2004-10-07 Cornell Research Foundation, Inc. Use of TGF-beta antagonists to inhibit tumor cell formation or progression
US20070185077A1 (en) * 2003-07-15 2007-08-09 Washington University Methods of treating, preventing and inhibiting cancer metastasis and tumor formation
US7527791B2 (en) * 2004-03-31 2009-05-05 Genentech, Inc. Humanized anti-TGF-beta antibodies
WO2007050793A2 (en) 2005-10-25 2007-05-03 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders
EP2230252A1 (de) 2006-03-13 2010-09-22 The Johns Hopkins University Erhöhung der endothelialen Thromboresistenz
EP2918288B1 (de) 2006-10-03 2017-08-16 Genzyme Corporation Verwendung von TGF-beta-Antagonisten zur Behandlung von Kleinkindern mit dem Risiko der Entwicklung von bronchopulmonaler Dysplasie
JP5886212B2 (ja) 2010-12-27 2016-03-16 Ｌｓｉｐファンド運営合同会社 ｉＰＳ細胞とその製造法
EP2714735B1 (de) * 2011-06-03 2021-07-21 XOMA Technology Ltd. Tgf-beta-spezifische antikörper
US20140308275A1 (en) 2011-07-27 2014-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods for diagnosing and treating myhre syndrome
AU2011379972B2 (en) 2011-10-26 2016-05-12 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
EP3553169B1 (de) 2011-12-28 2021-11-03 Kyoto Prefectural Public University Corporation Normalisierung der züchtung von hornhautendothelzellen
KR20180128097A (ko) * 2012-02-10 2018-11-30 재패닉 코포레이션 비 인간 줄기세포의 배양 상등액을 원료로 하는 화장품 또는 피부 재생 촉진제, 및 단백질의 이온 도입 방법
US20150284455A1 (en) * 2012-11-06 2015-10-08 Scholar Rock, Inc. Compositions and methods for modulating cell signaling
JP2016521283A (ja) 2013-05-06 2016-07-21 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 成長因子モジュレーションのための組成物および方法
RU2712967C2 (ru) 2013-10-31 2020-02-03 Киото Прифекчурал Паблик Юниверсити Корпорэйшн Терапевтическое средство против заболеваний, связанных с гибелью клеток эндотелия роговицы, обусловленной состоянием эндоплазматического ретикулума
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
US10723793B2 (en) * 2015-06-12 2020-07-28 Ludwig Institute For Cancer Research, Ltd. TGF-β3 specific antibodies and methods and uses thereof
WO2017156500A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgfb1-binding immunoglobulins and use thereof
AU2017268234A1 (en) 2016-05-17 2018-12-13 Genentech, Inc. Stromal gene signatures for diagnosis and use in immunotherapy
JP2019131471A (ja) * 2016-05-27 2019-08-08 国立大学法人 東京大学 抗ＴＧＦ−ｂｅｔａ３抗体およびその使用
JP6948059B2 (ja) * 2017-09-28 2021-10-13 学校法人 川崎学園 ｍｉＲ−１４０−３ｐによる骨芽細胞からのオステオカルシン産生促進
MX2020004567A (es) 2017-11-06 2020-08-13 Genentech Inc Metodos diagnosticos y terapeuticos para el cancer.
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
CN117510630A (zh) 2020-03-19 2024-02-06 基因泰克公司 同种型选择性抗TGF-β抗体及使用方法
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0418234B1 (de) * 1988-06-08 1994-03-23 Genentech, Inc. Nukleinsäure, die tgf-b3 kodiert, und ihre verwendung
US5236905A (en) * 1988-08-25 1993-08-17 Oncogen In vitro method of inhibition of HIV using transforming growth factor-.beta.

Also Published As

Publication number Publication date
JPH05509312A (ja) 1993-12-22
DE69129302T2 (de) 1998-12-03
EP0536275A1 (de) 1993-04-14
ES2120416T3 (es) 1998-11-01
EP0536275A4 (en) 1994-10-05
ATE165395T1 (de) 1998-05-15
AU8183891A (en) 1992-01-23
US5262319A (en) 1993-11-16
AU657913B2 (en) 1995-03-30
EP0536275B1 (de) 1998-04-22
DK0536275T3 (da) 1999-02-22
CA2084510A1 (en) 1991-12-26
WO1992000330A1 (en) 1992-01-09

Similar Documents

Publication Publication Date Title
DE69129302D1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
EP0683234A4 (de) ANTIKÖRPER GEGEN -g(b)-AMYLOID ODER DERIVATE DAVON UND SEINE VERWENDUNG.
EA200602015A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
DE60042693D1 (de) Dosierung für die behandlung mit anti erbb2-antikörpern
NO177526C (no) Fremgangsmåte for fremstilling av farmasöytisk aktive konjugater
ATE110265T1 (de) Verwendung von sigma-rezeptor-liganden zur herstellung eines anxiolytikums.
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
DE69129460T2 (de) Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
FI972703A0 (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
ATE398137T1 (de) Porphyromonas gingivalis antigene zur diagnose und behandlung von periodontitis
BR0116686A (pt) Anticorpos anti-cd28 silenciados e uso dos mesmos
ES2147365T3 (es) Un procedimiento para la preparacion del factor ix a partir de muestras biologicas.
DE69529272D1 (de) MONOKLONALER ANTIKÖRPER GEGEN DAS HUMANE Mx-PROTEIN MxA
ATE43610T1 (de) Acino-foetale differenzierungsproteine verbunden mit krebs des pankreas, antiserum und monoklonale antikoerper gegen diese proteine und verfahren zu ihrer herstellung.
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
PT998493E (pt) Epitopos de toxina semelhante a shigella e a sua utilizacao como vacinas e em diagnosticos
AU653332B2 (en) Synthetic peptides which contain sequences from factor VIIa, and the use thereof
ATE144286T1 (de) Monoklonale antikörper gegen den plasmin- antiplasmin komplex, verfahren zu ihrer herstellung sowie ihre verwendung
RU96123360A (ru) Способ лечения сепсиса у новорожденных

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: OSI PHARMACEUTICALS, INC., UNIONDALE, NEW YORK, US